Kynurenine 3‐mono‐oxygenase inhibitors attenuate post‐ischemic neuronal death in organotypic hippocampal slice cultures
Authors:
- 19 September 2002
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 82 (6) , 1465-1471
Abstract
Kynurenine 3‐mono‐oxygenase (KMO) inhibitors reduce 3‐hydroxykynurenine (3‐HK) and quinolinic acid (QUIN) neosynthesis and facilitate kynurenine metabolism towards kynurenic acid (KYNA) formation. They also reduce tissue damage in models of focal or transient global cerebral ischemia in vivo. We used organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation (OGD) to investigate KMO mechanism(s) of neuroprotective activity. Exposure of the slices to 30 min of OGD caused CA1 pyramidal cell death and significantly decreased the amount of KYNA released in the incubation medium. The KMO inhibitors (m‐nitrobenzoyl)‐alanine (30–100 µm) or 3,4‐dimethoxy‐[‐N‐4‐(nitrophenyl)thiazol‐2yl]‐benzenesulfonamide (1–10 µm) reduced post‐ischemic neuronal death and increased KYNA concentrations in slice incubation media. The maximal concentration of KYNA detected in the incubation media of slices treated with KMO inhibitors was approximately 50 nm and was too low to efficiently interact with α7 nicotinic acetylcholine receptors or with the glycineb site of N‐methyl‐d‐aspartate (NMDA) receptors. On the other hand, the addition of either 3‐HK or QUIN (1–10 µm) to OGD‐exposed hippocampal slices prevented the neuroprotective activity of KMO inhibitors. Our results suggest that KMO inhibitors reduce the neuronal death found in the CA1 region of organotypic hippocampal slices exposed to 30 min of OGD by decreasing the local synthesis of 3‐HK and QUIN.Keywords
This publication has 35 references indexed in Scilit:
- Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemiaCell Death & Differentiation, 2001
- Neuronal Apoptosis Induced by Pharmacological Concentrations of 3‐HydroxykynurenineJournal of Neurochemistry, 2000
- Kynurenine Hydroxylase Inhibitors Reduce Ischemic Brain Damage: Studies with (m-Nitrobenzoyl)-Alanine (mNBA) and 3,4-Dimethoxy-[-N-4-(Nitrophenyl)Thiazol-2YL]-Benzenesulfonamide (Ro 61-8048) in Models of Focal or Global Brain IschemiaJournal of Cerebral Blood Flow & Metabolism, 1999
- Synthesis and Biochemical Evaluation ofN-(4-Phenylthiazol-2-yl)benzenesulfonamides as High-Affinity Inhibitors of Kynurenine 3-HydroxylaseJournal of Medicinal Chemistry, 1997
- Glycine Causes Increased Excitability and Neurotoxicity by Activation of NMDA Receptors in the HippocampusExperimental Neurology, 1997
- Comparison of the Neurochemical and Behavioral Effects Resulting from the Inhibition of Kynurenine Hydroxylase and/or KynureninaseJournal of Neurochemistry, 1995
- Nicotinylalanine Increases the Formation of Kynurenic Acid in the Brain and Antagonizes ConvulsionsJournal of Neurochemistry, 1992
- Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activityGeneral Pharmacology: The Vascular System, 1992
- Modulation of Quinolinic and Kynurenic Acid Content in the Rat Brain: Effects of Endotoxins and NicotinylalanineJournal of Neurochemistry, 1991
- Presence of Kynurenic Acid in the Mammalian BrainJournal of Neurochemistry, 1988